#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

hyperparathyroidism as a cause of hypercalcemia in a patient with breast cancer


Authors: Kateřina Zajíčková
Authors‘ workplace: Endokrinologický ústav Praha
Published in: Čas. Lék. čes. 2010; 149: 546-548
Category: Case Report

Overview

Hypercalcemia associated with breast cancer arises either from metastatic bone disease or from paraneoplastic secretion of parathyroid hormone-related peptide. We report a female 69-year-old patient with invasive intraductal breast cancer and hypercalcemia (3,4 mmol/l) referred to endocrinologist. Standard care in oncology was refused and with respect to the presence of estrogenic receptors the patient accepted only antiestrogenic treatment. Bone scan revealed no skeletal metastasis. Entry laboratory exam confirmed hypercalcemia, hypophosphatemia and significantly elevated parathyroid hormone (793 ng/l). The patient complained of bone pain and dyspepsia. Neck ultrasound showed a multinodular goiter with particularly enlarged left lobe. Parathyroid gland scintigraphy revealed a possible parathyroid adenoma behind the lower pole of the left thyroid lobe. The patient underwent thyroidectomy with an excision of the parathyroid mass. Microscopic examination identified a benign adenomatous goitre and benign parathyroid adenoma. Postoperatively, both serum calcium and parathyroid hormone normalized. Replacement of calcium and vitamin D were initiated both with bisphosphonate with regard to newly diagnosed osteoporosis. This case demonstrates a patient with breast cancer and hypercalcemia unrelated to the malignant disease. Primary hyperparathyroidism should be considered as a possible cause of hypercalcemia in breast cancer patients in the setting of negative bone scan, elevated parathyroid hormone and mildly deteriorated bone mineral density.

Key words:
hypercalcemia, parathyroid hormone, breast cancer, primary hyperparathyroidism.


Sources

1. Stewart AF. Hyperparathyroidism, humoral hypercalcemia of malignancy, and the anabolic actions of parathyroid hormone and parathyroid hormone-related protein on the skeleton. J Bone Miner Res 2002; 17: 758–762.

2. Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, Keutmann HT, Wang CA, Potts JT Jr, Segre GV. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987; 33: 1364–1367.

3. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, Udesky J, Silverberg SJ. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008; 93: 3462–3470.

4. Fierabracci P, Pinchera A, Miccoli P, Conte PF, Vignali E, Zaccagnini M, Marcocci C, Giani C. Increased prevalence of primary hyperparathyroidism in treated breast cancer. J Endocrinol Invest 2001; 24: 315–320.

5. Tanaka Y. Primary hyperparathyroidism with breast carcinoma. Breast Cancer 2009; 17: 265–268.

6. Nulsson IL, Zedenius J, Yin L, Ekbom A. The association between primary hyperparathyroidism and malignancy : nationwide cohort analysis on cancer incidence after parathyroidectomy. Endocr Relat Cancer 2007; 14: 135–140.

Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental Hygienist
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#